Search Results

MC# 20-06
A Phase I, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors

MC# 18-02
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects with Solid Tumors and Non-Hodgkin’s Lymphoma

MC# 19-35
A Phase I/II Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

MC# 18-24
A Phase I/II, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination with NKTR-214 and/or Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies

MC# 19-17
A Phase I, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/Refractory Solid Tumors

MC# 20-15
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors

MC# 19-07
A Phase I Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors

MC# 19-08
A Phase I Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors

MC# 16-07
An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

MC# 16-09
A Phase I Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors

MC# 17-33
A Sequential 2-arm, Open-label Phase I Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors

MC# 17-24
A Phase I Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas